Puma Biotechnology (PBYI) Stock Forecast, Price & News

Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions

Is Puma Biotechnology a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Puma Biotechnology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PBYI, but not buy additional shares or sell existing shares.
View analyst ratings for Puma Biotechnology or view top-rated stocks.

When is Puma Biotechnology's next earnings date?

Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Puma Biotechnology.

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology, Inc. (NASDAQ:PBYI) released its earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05. The biopharmaceutical company had revenue of $45.70 million for the quarter, compared to analyst estimates of $45.07 million. Puma Biotechnology had a negative net margin of 24.42% and a negative trailing twelve-month return on equity of 843.16%. The company's revenue was down 53.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.40 EPS.
View Puma Biotechnology's earnings history.

What price target have analysts set for PBYI?

3 equities research analysts have issued 12-month price objectives for Puma Biotechnology's stock. Their forecasts range from $6.00 to $12.00. On average, they anticipate Puma Biotechnology's stock price to reach $9.25 in the next twelve months. This suggests a possible upside of 371.9% from the stock's current price.
View analysts' price targets for Puma Biotechnology or view top-rated stocks among Wall Street analysts.

Who are Puma Biotechnology's key executives?

Puma Biotechnology's management team includes the following people:

• Mr. Alan H. Auerbach, Founder, Chairman, Pres, CEO & Sec. (Age 52, Pay $5.69M) (LinkedIn Profile)
• Mr. Maximo F. Nougues, CFO & Principal Accounting Officer (Age 53, Pay $1.63M) (LinkedIn Profile)
• Mr. Douglas Hunt B.Sc., FRAPS, Sr. VP of Regulatory Affairs, Medical Writing & Project Management (Age 57, Pay $2.14M)
• Mr. Jeffrey Jerome Ludwig, Chief Commercial Officer (Age 56, Pay $4.61M)
• Dr. Alvin F. Wong, Chief Scientific Officer
• Mr. Mariann Ohanesian, Sr. Director of Investor Relations

Who are some of Puma Biotechnology's key competitors?

Some companies that are related to Puma Biotechnology include Pardes Biosciences (PRDS), Gelesis (GLS), Esperion Therapeutics (ESPR), Khosla Ventures Acquisition (KVSA), Arbutus Biopharma (ABUS), COMPASS Pathways (CMPS), Heron Therapeutics (HRTX), LianBio (LIAN), ALX Oncology (ALXO), BioXcel Therapeutics (BTAI), Tyra Biosciences (TYRA), Thorne HealthTech (THRN), Sernova (SEOVF), Silence Therapeutics (SLN) and Rigel Pharmaceuticals (RIGL).
View all of PBYI's competitors.

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and (CELG).

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Who are Puma Biotechnology's major shareholders?

Puma Biotechnology's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.71%), BlackRock Inc. (7.51%), Renaissance Technologies LLC (3.94%), Acadian Asset Management LLC (3.76%), Eversept Partners LP (3.17%) and Kynam Capital Management LP (1.45%). Company insiders that own Puma Biotechnology stock include Alan H Auerbach, Alvin F Wong, Ann Calby Miller, Douglas M Hunt, Jay M Moyes, Langley Steinert, Maximo F Nougues, Richard Paul Bryce and Troy Edward Wilson.
View institutional ownership trends for Puma Biotechnology.

Which major investors are selling Puma Biotechnology stock?

PBYI stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Assenagon Asset Management S.A., Vanguard Group Inc., Walleye Capital LLC, Acadian Asset Management LLC, Renaissance Technologies LLC, Kynam Capital Management LP, and PDT Partners LLC. Company insiders that have sold Puma Biotechnology company stock in the last year include Alan H Auerbach, Alvin F Wong, Ann Calby Miller, Douglas M Hunt, Langley Steinert, and Maximo F Nougues.
View insider buying and selling activity for Puma Biotechnology or view top insider-selling stocks.

Which major investors are buying Puma Biotechnology stock?

PBYI stock was acquired by a variety of institutional investors in the last quarter, including Eversept Partners LP, BlackRock Inc., Western Standard LLC, GSA Capital Partners LLP, Russell Investments Group Ltd., State Street Corp, Federated Hermes Inc., and XTX Topco Ltd.
View insider buying and selling activity for Puma Biotechnology or or view top insider-buying stocks.

How do I buy shares of Puma Biotechnology?

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Puma Biotechnology's stock price today?

One share of PBYI stock can currently be purchased for approximately $1.96.

How much money does Puma Biotechnology make?

Puma Biotechnology has a market capitalization of $88.15 million and generates $253.20 million in revenue each year. The biopharmaceutical company earns $-29.13 million in net income (profit) each year or ($1.200010) on an earnings per share basis.

How many employees does Puma Biotechnology have?

Puma Biotechnology employs 196 workers across the globe.

What is Puma Biotechnology's official website?

The official website for Puma Biotechnology is www.pumabiotechnology.com.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at (424) 248-6500, via email at [email protected], or via fax at 424-248-6501.